Indomethacin sensitizes resistant transformed cells to macrophage cytotoxicity

Hana Totary-Jain a,*, Ronit Vogt Sionov b, Ruth Gallily c

a Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
b Department of Developmental Biology and Cancer Research, IMRIC, The Hadassah Medical School–Hebrew University of Jerusalem, Israel
c The Lautenberg Center for General and Tumor Immunology, The Hadassah Medical School–Hebrew University of Jerusalem, Israel

ARTICLE INFO
Article history:
Received 28 February 2016
Received in revised form 15 May 2016
Accepted 16 May 2016
Available online 17 May 2016

Keywords:
Indomethacin
PGE2
Tumor cell resistance
Macrophage cytotoxicity
TNFα

ABSTRACT
Activated macrophages are well known to exhibit anti-tumor properties. However, certain cell types show intrinsic resistance. Searching for a mechanism that could explain this phenomenon, we observed that the supernatant of resistant cells could confer resistance to otherwise sensitive tumor cells, suggesting the presence of a secreted suppressor factor. The effect was abolished upon dialysis, indicating that the suppressor factor has a low molecular weight. Further studies showed that prostaglandin E2 (PGE2) is secreted by the resistant tumor cells and that inhibition of PGE2 production by indomethacin, a cyclooxygenase (COX) inhibitor, eliminated the macrophage suppression factor from the supernatant, and sensitized the resistant tumor cells to macrophage cytotoxicity. This study emphasizes the important role of tumor-secreted PGE2 in escaping macrophage surveillance and justifies the use of COX inhibitors as an adjuvant for improving tumor immunotherapy.

© 2016 The Authors. Published by Elsevier B.V. on behalf of European Federation of Immunological Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Activated macrophages have the propensity to kill tumor cells both in vitro and in vivo in virtue of their ability to produce tumor necrosis factor-α (TNFα), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and nitric oxide [1–3]. Usually the macrophages need to be activated in order to kill tumor cells. An exception is the ability of macrophages to eliminate teratocarcinoma cells and embryonic stem cells without the need for an external activation signal [4]. Several activation agents can increase the tumoricidal activity of macrophages, including the cytokines IFNγ, IL-12 and TNFα, whole bacteria such as Mycobacterium bovis Bacille Calmette-Guérin (BCG) and mycoplasma, and bacterial and yeast components such as lipopolysaccharide (LPS), zymosan and β-glucans [2,5–7].

The tumor microenvironment is comprised of a variety of non-malignant cells such as fibroblasts, stromal cells, endothelial cells, pericytes and a variety of immune cells that can make up to 90% of the total tumor volume [8]. Within the tumor microenvironment, the macrophages are exposed to a wide range of tumor-secreted factors as well as cytokines and chemokines secreted by immune cells, which modulate macrophage functions. Among these factors, TGFβ promotes macrophage polarization from an anti-tumor M1 to a pro-tumor M2 phenotype [9,10]. Other factors that can contribute to this polarization are the cytokines IL-4, IL-13 and IL-10 [10,11] and repeated activation of macrophages, which leads to loss of TNFα secretion and acquisition of high iNOS activity (our unpublished data). Indeed, the central macrophage product TNFα promotes the generation of immature myeloid-derived suppressor cells (MDSCs) [12], providing a negative feedback mechanism to tune the immune response. Alternatively activated M2 macrophages have a strikingly different gene expression profile compared with M1 macrophages and express a different combination of surface receptors (e.g., CD163), cytokines (e.g., IL-10), tumor growth factors (e.g., EGF, FGF1, TGFβ1), pro-angiogenic factors (e.g., VEGF), matrix remodeling factors (e.g., fibrin and matrix metalloproteinases) and chemokines (e.g., CCL17/TARC, CCL22/MDC and CCL24/Eotaxin-2) [10,11]. In addition, M2 macrophages produce lower levels of ROS, but express higher levels of arginase I and indoleamine 2,3-dioxygenase (IDO) [10,11]. Additional subtypes of macrophages

Abbreviations: COX, cyclooxygenase; PGE2, prostaglandin E2; MΦ, macrophages; NSAID, non-steroid anti-inflammatory drugs; TNF, tumor necrosis factor α.
* Corresponding author.
E-mail addresses: totaryjainh@health.usf.edu (H. Totary-Jain), ronit.sionov@mail.huji.ac.il (R.V. Sionov), ruthg@ekmd.huji.ac.il (R. Gallily).

http://dx.doi.org/10.1016/j.imlet.2016.05.011
0165-2478/© 2016 The Authors. Published by Elsevier B.V. on behalf of European Federation of Immunological Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
have also been identified [13], suggesting a broad spectrum of macrophage activation stages [6].

We have observed that while some tumor cells are susceptible to macrophage cytotoxicity, others are resistant. The aim of our study was to characterize the mechanisms involved in conferring macrophage resistance upon tumor cells. This study shows that a low molecular weight factor secreted by tumor cells, defined as prostaglandin E2 (PG\textsubscript{E}\textsubscript{2}), prevents macrophage activation required for tumor cytotoxicity. Inhibition of PG\textsubscript{E}\textsubscript{2} production, using the non-steroid anti-inflammatory drug (NSAID) indomethacin, not only restored macrophage activation, but also conferred sensitivity of the otherwise resistant tumor cells to macrophage cytotoxicity.

2. Material and methods

2.1. Mice

C57BL/6 mice were obtained from the Animal Breeding Farm, Hebrew University-Hadassah Medical School of Jerusalem. All experiments involving animals were approved by the Hebrew University’s Institutional Animal Care and Use Committee.

2.2. Cell cultures

Bone-marrow-derived macrophages (BMM\Phi) were obtained from bone marrow cells (usually \(\sim 3 \times 10^8\) cells per mouse) harvested from the femur and tibia of 6–8-week old female C57BL/6 mice, which were cultivated in DMEM supplemented with 15% heat-inactivated fetal calf serum (FCS), 5% heat-inactivated horse serum, 30% L929 cell conditioned medium (LCM), 2 mM L-glutamine, 10 mM HEPES, 100 U/ml penicillin and 100 mg/ml streptomycin. The macrophages were cultivated on 9 cm diameter bacteriological grade culture dishes (Miniplast, Ein Shemer, Israel) and were used as effectors 10–21 days after bone marrow seeding.

LCM was prepared by seeding \(10^6\) L929 cells in 20 ml DMEM supplemented with 10% FCS in a 75 cm\(^2\) tissue culture flask (Nunclon, Denmark). Following 4–5 days incubation, when a monolayer had been reached, the supernatant was collected and sterile filtered.

A9 fibrosarcoma cells (a C\textsubscript{3}H fibrosarcoma derived from L929 cells), L929 fibrosarcoma cells, NIH3T3 mouse embryonic fibroblast-like cells and M109 Madison lung carcinoma cells were grown in DMEM supplemented with 5% heat-inactivated FCS, 2 mM L-glutamine, 10 mM HEPES and antibiotics. The FCS was used from batches that did not pre-activate macrophages. All cell cultures were incubated at 37\(^\circ\)C in a humidified incubator containing 5% CO\textsubscript{2}. All cultures were routinely tested for being mycoplasma-free.

2.3. Cytotoxicity assay

Cytotoxicity assay was performed as described previously [4]. Briefly, target cells in the log phase of growth were pulsed with 1 \(\mu\)Ci/ml of \(^{3}H\)thymidine (sp. Act 5 Ci/mM; American Radiolabeled Chemicals, Inc.) for 24 h, washed in PBS, trypsinized and resuspended in DMEM with 10% FCS, 2 mM L-glutamine, and 10 mM HEPES. Ten thousand target cells were added to 1 \(\times 10^5\) BMM\Phi in 96 flat-bottomed microwells (Nunclon, Denmark) in 300 \(\mu\)l DMEM supplemented with 10% heat-inactivated FCS in the absence or presence of 1 \(\mu\)g/ml LPS (Escherichia coli 055:B5, Bacto\textsuperscript{\textregistered}, Difco). Following 72 h, the supernatants (300 \(\mu\)l) were harvested from the microwells, diluted with Insta-Gel (Packard, Downers Grove, Illinois) and the radioactivity counted. The samples were kept at 4\(^\circ\)C for 24 h prior to counting. Percentage specific cytosis was calculated by the following formula: % Cytosis = [(E-SR)/(T-SR)] \times 100% where E is the d.p.m. of the supernatant from co-culture of target cells and macrophages, SR the spontaneous release in d.p.m. of an equal number of target cells in medium without macrophages, and T the total d.p.m. uptake of target cells.

For determination of target cell sensitivity to TNF\textalpha, 5000 \(^{3}H\)thymidine-labeled cells were seeded in 100 \(\mu\)l DMEM with 5% FCS in each well of a 96-well plate. At the following day, 50 \(\mu\)l of various concentrations of TNF\textalpha (Genentech Inc., San Francisco) were added, followed by a 3-day incubation at 37\(^\circ\)C. The extent of cell death was determined by measuring the released radioactivity as described above. Control wells got 50 \(\mu\)l of medium. Alternatively, cells were incubated with TNF\textalpha in the presence of 2 \(\mu\)g/ml Actinomycin D (Sigma), and the extent of cell death determined 18 h later.

2.4. Production of TNF\textalpha by activated macrophages and determination of TNF\textalpha titer

One hundred thousand BMM\Phi were added to each of the 96 flat-bottomed microwells in 100 \(\mu\)l DMEM with 10% heat-inactivated FCS, 18 h prior to activation. The activation step was performed by changing the medium to DMEM without FCS or cell culture supernatant in the same medium, either in the absence or presence of 1 \(\mu\)g/ml LPS, followed by incubation for 24 h. Macrophage supernatants were assayed for TNF\textalpha by bioassay as described previously [4]. Briefly, 4 \(\times 10^6\) Cl-7 cells were plated per 96 flat-bottomed microwell in 100 \(\mu\)l DMEM with 5% FCS. On the following day, 3-fold dilutions of test supernatants and control media were made in the wells, followed by immediate addition of actinomycin D (Sigma; 2 \(\mu\)g/ml, final concentration). The cultures were incubated for 20 h at 37\(^\circ\)C, and the survived Cl-7 cells were stained for 10 min with crystal violet (0.2% in 2% ethanol), washed with running tap water and allowed to dry. The destruction of the Cl-7 monolayer was determined by the amount of light at (550 nm) absorbed by the residual stained cells in the wells using a Dynatech MicroElisa Reader (Artek, Farmingdale, NY). The \(50_0\) titer of TNF\textalpha was defined as the reciprocal of the dilution of the test solution required to destroy 50% of the target cell monolayer, as compared to control samples.

2.5. Conditioned medium of cultured cells

\(2 \times 10^5\) cells were seeded per well in a 24-well culture plate (Nunclon, Denmark) in 1.5 ml DMEM with 5% FCS. After 24 h, the medium was exchanged to fresh medium, and the supernatant collected 24 h later. The supernatants were centrifuged at 1200 rpm for 15 min, and kept at 4\(^\circ\)C until use.

2.6. Surface TNF\textalpha receptor binding assay

The assay was performed in accordance to Holtmann & Wallach [14]. TNF\textalpha was labeled with \(^{125}I\) by the chloramine-T method to a specific radioactivity of 1500 Ci/mmol. One million target cells were seeded in growth medium in tissue culture plates the day before assay. On the following day, the cells were washed and incubated on ice for 2 h with 0.5 mM \(^{125}I\)-TNF\textalpha in the absence or presence of excess unlabeled TNF\textalpha (20 \(\mu\)M) in PBS containing 140 mM NaCl, 1.5 mM KH\textsubscript{2}PO\textsubscript{4}, 8 mM Na\textsubscript{2}HPO\textsubscript{4}, 2.7 mM KCl, 0.5 mM MgCl\textsubscript{2}, 0.9 mM CaCl\textsubscript{2}, 0.5% bovine serum albumin (BSA) and 15 mM sodium azide. Thereafter, the cells were washed three times in the binding buffer, detached in Ca\textsuperscript{2+}- and Mg\textsuperscript{2+}-free PBS containing 5 mM EDTA and transferred to vials for radioactivity measurements. Specific binding of TNF\textalpha was calculated by subtracting the values of binding observed in the presence of an excess of unlabeled TNF\textalpha from the value of binding observed with \(^{125}I\)-TNF\textalpha alone.
2.7. Determination of prostaglandin E2 (PGE2) concentration

The PGE2 concentrations in cell supernatants were determined by radioimmunoassay. 100 μl of sample, buffer alone or PGE2 standard (0.15–10 ng/ml; Sigma) were mixed with 100 μl 0.01 M sodium phosphate buffer pH 7.4 containing 0.15 M NaCl, 0.1% BSA, 0.1% NaN3 and 500 μl anti-serum to PGE2 (Bio-Makor; diluted 1:10). Following a 30 min incubation at 4°C, 100 μl of [5,6,8,11,12,14,15-3H(N)]-PGE2 (0.1 μCi/ml, Amersham, England) was added at a dilution giving 50,000–100,000 d.p.m. After 60 min incubation at 4°C, 200 μl of a dextran coated charcoal solution [1% charcoal with 0.1% dextran (MW 35,000–45,000; Sigma)] in sodium phosphate buffer were added, except for samples intended for total radioactive read. After vigorous mixing, the samples were incubated for 10 min at 4°C, followed by centrifugation at 3000 rpm for 15 min at 4°C. 250 μl of the supernatant was mixed with 3 ml of Insta-gel, and the radioactivity was measured in a β-counter. No antibody was added to the blank samples. The percentage of bound radioactive PGE2 was calculated according to \([S – B]/[T – B] \times 100\%\), where S is the d.p.m. of the sample, T the d.p.m. of the blank sample and B the total radioactive amount. The limitation of this assay was 5 pg/ml PGE2.

2.8. Statistical analysis

Experiments were repeated 3–5 times. The arithmetic average of all experiments performed is given. Statistical significance was assessed by the one-tail distribution-free Mann-Whitney U test. Error bars represent standard error. Differences were considered significant when the p value was 0.05 or less.

3. Results

3.1. Differential sensitivity of transformed cells to macrophage cytotoxicity

The aim of this study was to understand why some transformed cells are resistant to macrophage-mediated killing. We observed that M109 lung carcinoma cells and NIH3T3 fibroblast-like cells were relatively resistant, whereas A9 and L929 fibroblast-like cells were highly sensitive to killing by activated macrophages (Fig. 1A). None of these cells were killed by non-activated macrophages, as expected. The resistance could be due to intrinsic resistance to TNFα-mediated killing, the major mediator of macrophage cytotoxicity, or the secretion of a macrophage suppressor factor by the tumor cells. We first analyzed whether the NIH3T3 and M109 cells express TNF receptors by using the TNFα binding assay [14]. We found that NIH3T3 and M109 bound even more 125I TNFα per cell than the macrophage-sensitive L929 cells (Table 1), thus excluding the lack of TNF receptors as the reason for their resistance to macrophage cytotoxicity. It could be that the cells are resistant to the cytotoxic effect of TNFα. To test this possibility, the cells were incubated in various dilutions of activated macrophage-conditioned medium, which contained an active TNFα S90 titer of 99,170 when analyzed on C-7 cells in the presence of actinomycin D. This assay shows that both NIH3T3 and M109 responded to the macrophage-conditioned medium by cell death (Fig. 1B).

We next studied whether the resistant tumors secrete a factor that prevents macrophage activation. For this purpose, macrophages were incubated with the conditioned medium of the transformed cells in the absence or presence of 1 μg/ml LPS, and following a 24 h-incubation at 37°C, the amount of TNFα secreted by the macrophages was determined. We observed that, while the conditioned medium of A9 cells did not interfere with the macrophages’ ability to secrete TNFα in response to LPS, the conditioned media of NIH3T3 and M109 cells almost completely blocked TNFα secretion by macrophages (90–98% inhibition; Fig. 1C). These data suggest that the transformed cells indeed secrete a macrophage inhibitory factor.

In order to study whether the inhibitory factor has a low or high molecular weight, we dialyzed the cell conditioned media or control medium against PBS for 48 h and then against DMEM to restore essential nutrients using a dialysis tube with an MW cutoff of 10,000 Da. The dialyzed conditioned media were analyzed for their effects on LPS-induced TNFα secretion by macrophages. After dialysis, the conditioned media of NIH3T3 and M109 had lost their ability to inhibit TNFα secretion, and they even enhanced its production (Fig. 1D). This indicates the presence of a low molecular weight inhibitory factor in the conditioned media.

3.2. Identification of PGE2 as the macrophage inhibitory factor

Since it has been reported that the low-molecular weight biochemical compound prostaglandin E2 (PGE2) can inhibit TNFα secretion from macrophages [15], we wondered whether our inhibitory factor is PGE2. We first analyzed the presence of PGE2 in the conditioned media, and observed that both NIH3T3 and M109 cells produced high levels of PGE2, while PGE2 couldn’t be detected in the conditioned media of A9 cells (Table 2). We then analyzed the effect of various concentrations of PGE2 on TNFα secretion by macrophages, and surprisingly observed a dose-dependent effect where high PGE2 concentrations (from 1 nM–1 μM) strongly inhibited TNFα secretion, while low concentrations (especially at 0.1–1 pM) strongly enhanced it (Fig. 2A). The synergistic effect of low PGE2 concentrations on TNFα secretion might explain why the dialyzed conditioned medium even enhanced its secretion by LPS-stimulated macrophages (Fig. 1D). In order to validate that the PGE2 secreted from NIH3T3 and M109 is the factor that inhibited macrophage activation, the cells were treated with the cyclooxygenase (COX) inhibitor indomethacin, and the resulting conditioned medium was analyzed for their ability to affect TNFα production. Indeed, indomethacin abolished the macrophage inhibitory effect of the conditioned medium and even enhanced TNFα secretion (Fig. 2B). The PGE2 concentration in the conditioned medium was negligible in the presence of indomethacin (undetectable in the NIH3T3 conditioned media, while 10 ng/ml in the M109 conditioned media). In light of these encouraging data, it was intriguing to determine whether indomethacin could sensitize the resistant cells to macrophage cytotoxicity. For this purpose, NIH3T3, M109

| Cell lines | Specific binding (cpm) |
|------------|------------------------|
| NIH3T3     | 10,427                 |
| M109       | 12,778                 |
| L929       | 4045                   |

| Cell lines | PGE2 conc in CM |
|------------|-----------------|
| NIH3T3     | 502 pg/ml (1.4 nM) |
| M109       | 397 pg/ml (1.1 nM) |
| A9         | n.d.             |
| MEF        | 185 pg/ml (0.5 nM) |
and A9 cells were incubated with macrophages with LPS in the absence or presence of 50 μM indomethacin, and the extent of cell killing was measured after 3 days of co-cultivation. Indeed, indomethacin sensitized the resistant tumor cells to macrophage cytotoxicity (Fig. 2C). Further studies showed that when the macrophage–sensitive A9 cells were incubated with macrophages that have been pre-incubated with the resistant NIH3T3 or M109 cells, the cell killing was reduced by 75% (Fig. 2D). This reduction in cell killing could be reversed by treating the co-cultures with indomethacin (Fig. 2D), further emphasizing the central role of PGE2 in mediating the macrophage inhibitory effect. This is further manifested by the suppression of A9 cell killing when PGE2 was added to the co-culture of A9 and macrophages (Fig. 2E). Maximum inhibition was obtained at 1–10 nM PGE2 (47–51% inhibition; Fig. 2E).

4. Discussion

Our pioneering study, performed in the late 1980’s, is fully relevant today in light of the current recognition that PGE2 is a key player in the carcinogenesis of colon cancer and several other cancer cell types [16–19], along with the introduction of aspirin in the clinics for the prevention of colon cancer [20,21]. During the years, it has been repeatedly shown that PGE2 suppresses diverse macrophage functions [22–26] and may even promote the shift towards the M2 phenotype [27–30] as well as the appearance of myeloid-derived suppressor cells with tumor-promoting function [31]. Other studies have demonstrated PGE2 production by various cancer cells [27,32,33,34–36], besides being produced by the macrophages themselves [37,38]. Our study combines these two issues showing that tumor-secreted PGE2 protects the tumor cells from macrophage cytotoxicity, a tumor immune escape mechanism that can be overcome by the drug indomethacin. Indomethacin and aspirin belong to the same group of non-steroid anti-inflammatory drugs (NSAIDs), and their benefits as adjuvants in cancer therapy seem thus to be of a dual nature. Namely, by preventing PGE2 production in the tumor cells, these drugs may directly inhibit PGE2–dependent tumor cell growth, and, simultaneously, increase macrophage cytotoxicity towards the tumor cells (Fig. 3). Both mechanisms contribute to the reduction of the tumor cell mass. Our study suggests a mechanistic explanation for the anti-tumor effects observed for indomethacin in various tumor models (e.g., [39–41]).

The dose-dependent effects of PGE2 observed by us on macrophage secretion of TNFα has also been observed by another research group [42]. That group observed that the differential effects of PGE2 are mediated by changes in the intracellular cAMP/cGMP ratio [42]. A dose-dependent effect of PGE2 on macrophage adhesion and migration has also recently been documented [42]. An interesting fact is that reducing the PGE2 level by indomethacin may not only prevent the inhibitory effect of PGE2 on macrophages, but may even lead to such low levels that the

![Fig. 1](https://example.com/fig1.png)

**Fig. 1.** (A) The sensitivity of various transformed cells to activated macrophage cytotoxicity. 1 × 10⁴ target cells were incubated with 1 × 10⁵ BMMΦ in the presence of 1 μg/ml LPS for 3 days. In the absence of LPS, there was no killing of any cells. p < 0.05 for M109/NIH3T3 versus A9/L929. (B) Cell sensitivity to TNFα. NIH3T3, M109 and A9 cells were incubated in various dilutions of activated macrophage-conditioned medium (BMMΦ-CM) in the presence of 2 μg/ml actinomycin D, and the extent of cell death determined 18 h later. (C) Inhibition of TNFα secretion by the conditioned media of transformed cells. One hundred thousand macrophages were incubated in serum-free medium or in conditioned media (CM) collected from NIH3T3, M109 or A9 cells, in the absence or presence of 1 μg/ml LPS for 24 h, and the amount of active TNFα secreted was determined as described in the Section 2.4. The relative TNFα secretion by macrophages in the presence of conditioned medium is presented in comparison to control medium. p < 0.05 for M109 CM and NIH3T3 CM versus control medium and A9 CM. (D) The suppressor factor is lost upon dialysis of the conditioned media. Conditioned media were dialyzed for 48 h against PBS, and then against DMEM, using a dialysis tube with a cut-off of 10,000 Da. The effect of the dialyzed conditioned media (dCM) on LPS-induced TNFα secretion by macrophages was analyzed. The data are presented as relative TNFα secretion by macrophages in the presence of dialyzed conditioned medium in comparison to dialyzed control medium, p < 0.05 for NIH3T3 dCM and M109 dCM versus dialyzed control medium.
tumoricidal effect of macrophages is enhanced. Indomethacin even increased the tumoricidal effect of activated macrophages on A9 cells that barely produce PGE₂ (Fig. 2C). This might be due to inhibition of PGE₂ production by the macrophages themselves during co-cultivation, where the negative feedback mechanism triggered upon macrophage activation is interrupted.

Of note, we could only reach up to 50% inhibition of A9 cell killing by macrophages when adding PGE₂, even though the higher con-
Fig. 3. The Tumor-PGE2-Macrophage Cross-Talk. Tumor cells produce PGE2 that is sometimes necessary for tumor autonomous cell growth, and at the same time suppresses macrophage activation required for anti-tumor function. Interruption of this cross-talk by indomethacin, restores the tumoricidal macrophage function that contributes to limit tumor growth.

centration (10 nM) completely blocked TNFα secretion. This might be due to the induction of another tumoricidal factor, such as the nitric oxide radical by PGE2 [44]. Nitric oxide has been shown to be involved in macrophage killing of L929 fibrosarcoma cells [3]. This scenario might also explain how PGE2 can induce tumoricidal activity of resident macrophages on L929 cells in the absence of any other activation signal [45]. Thus, PGE2 may support some anti-tumor macrophage activities despite abolishing TNFα production. This duality of PGE2 action might be important for maintaining essential macrophage functions under conditions where excessive immune responses are suppressed.

Altogether, our study sheds new light on the tumor cell-macrophage interrelationship, where macrophage tumoricidal activity can be regained by preventing excessive PGE2 production using the NSAID drug indomethacin. Tumor-secreted PGE2 likely acts in concert with other immune suppressive factors such as TGFβ [9], based on the observation that indomethacin couldn’t reverse macrophage killing of A9 cells when co-cultured in the presence of resistant transformed cells to a level similar to that observed in their absence (Fig. 2D). Our data would therefore suggest a potential use of indomethacin as an adjuvant agent in cancer immunotherapy that ought to be combined, for instance, with a TGFβ inhibitor.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgments

We are in depth grateful to Prof. David Wallach for doing the TNFα binding assay on our cell lines. This work was supported by the Concern Foundation of Los Angeles Society of Research Associates of the Lautenberg Center. HTJ is supported by the NIH, National Heart, Lung, and Blood InstituteR00HL109133 add space and R01HL128411.

References

[1] K. Kawata, A. Iwai, D. Muramatsu, S. Aoki, H. Uchiyama, M. Okabe, S. Hayakawa, A. Takaoka, T. Miyazaki, Stimulation of macrophages with the beta-glucan produced by aureobasidium pullulans promotes the secretion of tumor necrosis factor-related apoptosis inducing ligand (TRAIL), PLoS One 10 (2015) e0124809.
[2] K.B. Long, G.L. Beatty, Harnessing the antitumor potential of macrophages for cancer immunotherapy, Oncoimmunology 2 (2013) e26860.
[3] F.R. Nascimento, E.A. Gomes, M. Russo, A.P. Lepidi, Interferon regulatory factor (IRF)-1 is a master regulator of the cross talk between macrophages and L929 fibrosarcoma cells for nitric oxide dependent tumoricidal activity, PLoS One 10 (2015) e0117782.
[4] R.V. Sonov, R. Gallily, Engagement and intracellular killing of F9 teratocarcinoma cells by non-activated murine macrophages, Int. Immunol. 2 (1990) 291–301.
[5] B. Ruffell, L.M. Cousens, Macrophages and therapeutic resistance in cancer, Cancer Cell 27 (2015) 462–472.
[6] D.M. Mosser, J.P. Edwards, Exploring the full spectrum of macrophage activation, Nat. Rev. Immunol. 8 (2008) 958–960.
[7] S. Caplan, R. Gallily, Y. Barenholz, Characterization and purification of a mycoplasma membrane-derived macrophage-activating factor, Cancer Immunol. Immunoother. 39 (1994) 27–33.
[8] R.V. Sonov, Z.G. Fridlender, Z. Granot, The multifaceted roles neutrophils play in the tumor microenvironment, Cancer Microenviron. 8 (2015) 125–158.
[9] R.A. Flavell, S. Sanjabi, S.H. Wrezinski, P. Licona-Limon, The polarization of immune cells in the tumour environment by TGFbeta, Nat. Rev. Immunol. 10 (2010) 554–567.
[10] M.R. Galdiero, E. Bonavita, I. Barajon, C. Garlanda, A. Mantovani, S. Jaillon, Tumor associated macrophages and neutrophils in cancer, Immunobiology (2013).
[11] A. Mantovani, P. Allavena, The interaction of anticancer therapies with tumor-associated macrophages, J. Exp. Med. 212 (2015) 435–445.
[12] M. Sade-Feldman, J. Kanterman, E. Ish-Shalom, M. Elnekave, E. Horwitz, M. Banayash, Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation, Immunity 38 (2013) 541–554.
[13] Y. Tatano, T. Shimizu, H. Tomioka, Unique macrophages different from M1/M2 macrophages inhibit T cell mitogenesis while upregulating Th17 polarization, Sci. Rep. 4 (2014) 4146.
[14] H. Holtmann, D. Wallach, Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate, J. Immunol. 139 (1987) 1161–1167.
[15] S.L. Kunkel, R.C. Wiggins, S.W. Chensue, J. Larrick, Regulation of macrophage tumor necrosis factor production by prostaglandin E2, Biochem. Biophys. Res. Commun. 137 (1986) 404–410.
[16] B. Liu, L. Qu, S. Yan, Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity, Cancer Cell. Int. 15 (2015) 106.
[17] D. Wang, L. Fu, H. Sun, L. Guo, R.N. DuBois, Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice, Gastroenterology 149 (2015) 1884–1895, e1884.
[18] Y. Pan, Y. Jiang, L. Tan, M.K. Ravoori, M. Gagea, V. Kundra, S.M. Fischer, P. Yang, Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis, Oncotarget 6 (2015) 38816–38826.
[19] G. O’Callaghan, A. Houston, P prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br. J. Pharmacol. 172 (2015) 5235–5250.
[20] X. Garcia-Albeniz, A.T. Chan, Aspirin for the prevention of colorectal cancer, Best Pract. Res. Clin. Gastroenterol. 25 (2011) 461–472.
[21] N. Nelson, On trial: evidence from using aspirin to prevent cancer, J. Natl. Cancer Inst. 107 (2015).
[22] J.G. Kim, Y.S. Hahn, IFN-gamma inhibits the suppressive effects of PGE2 on the production of tumor necrosis factor-alpha by mouse macrophages, Immunol. Invest. 29 (2000) 257–269.

[23] X. Qian, J. Zhang, J. Liu, Tumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP/PKA signaling pathway, J. Biol. Chem. 286 (2011) 2111–2120.

[24] Z. Konopski, R. Seljeld, T. Eskeland, Cytokines and PGE2 modulate the phagocytic function of the beta-glucan receptor in macrophages, Scand. J. Immunol. 37 (1993) 587–592.

[25] C. Strassmann, V. Patil-Koeta, F. Finkelman, M. Fong, T. Kambayashi, Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2, J. Exp. Med. 180 (1994) 2365–2370.

[26] M. Sokolowska, L.Y. Chen, Y. Liu, A. Martinez-Anton, H.Y. Qi, C. Logan, S. Afsaaty, Y.H. Park, D.L. Kastner, J.J. Chae, J.H. Shelhamer, Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and intracellular cyclic AMP in human macrophages, J. Immunol. 194 (2015) 5472–5487.

[27] M. Heusinkveld, P.J. de Vos van Steenwijk, R. Goedemans, T.H. Ramwadhdoebe, A. Gorter, M.J. Welters, T. van Hall, S.H. van der Burg, M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ T1h cells, J. Immunol. 187 (2011) 1157–1165.

[28] L. Liu, D. Ge, L. Ma, J. Mei, S. Liu, Q. Zhang, F. Ren, H. Liao, Q. Pu, T. Wang, Z. You, Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer, J. Thorac. Oncol. 7 (2012) 1091–1100.

[29] B. Luan, Y.S. Yoon, J. Le Lay, K.H. Kaestner, S. Hedrick, M. Montminy, CREB pathway links PGE2 signaling with macrophage polarization, Proc. Natl. Acad. Sci. U. S. A. 112 (2015) 15642–15647.

[30] Q. Zhang, D.J. Cai, B. Li, Ovarian cancer stem-like cells elicit the polarization of M2 macrophages, Mol. Med. Rep. 11 (2015) 4685–4693.

[31] J. Chang, J. Nager, B. Yao, X. Fan, B. Zhang, R.C. Harris, M.Z. Zhang, Prostaglandin E receptor 4 (EP4) promotes colon tumorigenesis, Oncotarget 6 (2015) 33500–33511.

[32] Y. Sasaki, Y. Nakatani, S. Hara, Role of microosomal prostaglandin E synthase-1 (mPGES-1)-derived prostaglandin E2 in colon carcinogenesis, Prostag. Other Lipid Mediat. 121 (2015) 42–45.

[33] E. Half, X.M. Tang, K. Gwys, A. Sahin, K. Wathen, F.A. Sincorpe, Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ, Cancer Res. 62 (2002) 1676–1681.

[34] A.C. Abrahao, R.M. Castilho, C.H. Squarize, A.A. Molinolo, D. dos Santos-Pinto Jr., J.S. Gurtland, A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation, Oral Oncol. 46 (2010) 880–887.

[35] J.E. Rundhaug, M.S. Simper, L. Surh, S.M. Fischer, The role of the EP receptors for prostaglandin E2 in skin and skin cancer, Cancer Metastasis Rev. 30 (2011) 465–480.

[36] K. Kaminska, C. Szczylzy, F. Lian, A.M. Czarnecka, The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy, Future Oncol. 10 (2014) 2177–2187.

[37] E. Kuroda, U. Yamashita, Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice, J. Immunol. 170 (2003) 757–764.

[38] Y. Endo, K. Blinova, T. Romantseva, H. Golding, M. Zaitseva, Differences in PGE2 production between primary human monocytes and differentiated macrophages: role of IL-1beta and TRIF/IRF3, PLoS One 9 (2014) e89517.

[39] C.M. Moon, J.H. Kwon, J.S. Kim, S.H. Oh, K. Jin Lee, J.J. Park, S. Park, S.H. Hong, J.H. Cheon, T.I. Kim, W.H. Kim, Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH1/185 and activating PPARγ in colorectal cancer, Int. J. Cancer 134 (2014) 519–529.

[40] S. Santander, C. Cebrian, P. Esquivias, B. Conde, F. Esteva, P. Jimenez, J. Ortego, A. Lanas, E. Piazuelo, Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice, Int. J. Oncol. 40 (2012) 527–534.

[41] E.M. Connolly, J.H. Harmey, T. O’Grady, D. Foley, G. Roche-Nagle, E. Kay, D.J. Boucher-Hayes, Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer, Br. J. Cancer 87 (2002) 231–237.

[42] H. Renz, J.H. Gong, A. Schmidt, M. Nain, D. Gemsa, Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides, J. Immunol. 141 (1988) 2388–2393.

[43] I.C. Osma-Garcia, C. Punzon, M. Fresno, M.D. Diaz-Munoz, Dose-dependent effects of prostaglandin E2 in macrophage adhesion and migration, Eur. J. Immunol. (2015).

[44] S. Milano, F. Arcolee, M. Dieli, R. D’Agostino, P. D’Agostino, G. Deucci, E. Cillari, Prostaglandin E2 regulates inducible nitric oxide synthase in the murine macrophage cell line J774, Prostaglandins 49 (1995) 105–115.

[45] M.E. Snider, R.H. Fertel, B.S. Zwillin, Prostaglandin regulation of macrophage function: effect of endogenous and exogenous prostaglandins, Cell. Immunol. 74 (1982) 234–242.